McKesson oncologist survey report details the state of cell and gene therapy adoption and barriers

Genetic “Trojan horse” selectively kills cancer cells linked to Kaposi’s sarcoma, UC Davis study shows

In a preclinical study, UC Davis Comprehensive Cancer Center scientists developed a highly targeted gene therapy that could revolutionize treatment for cancers linked to a common herpesvirus, with minimal side effects.

October 03, 2025

Vol.51 No.36

Clinical Trials & Tribulations

An overlooked immune cell population may offer new direction for cell and gene therapy

Cell and gene therapies have made incredible strides over the past decade. The 2024 FDA approvals of the first T-cell receptor therapy for the treatment of metastatic synovial sarcoma and the first tumor-infiltrating lymphocyte therapy for the treatment of unresectable or metastatic melanoma mark a significant turning point for solid tumor treatment.xxx:more

John Zaia, virologist and gene therapy pioneer, dies at 82

John A. Zaia, director of the Center for Gene Therapy at City of Hope, died on Feb. 11 following a battle with pancreatic cancer. He was 82.

February 21, 2025

Vol.51 No.07

By Samantha Bonar and Abe Rosenberg

In Brief

OmniaBio opens commercial manufacturing facility in Canada, bringing cell and gene therapies to patients

OmniaBio Inc. announced the opening of a new North American cell and gene therapy manufacturing and artificial intelligence center of excellence, which is now Canada’s largest contract development and manufacturing organization facility dedicated to CGT.

October 25, 2024

Vol.50 No.40

Clinical Roundup

Xcell Biosciences, AmplifyBio expand collaboration with cell and gene therapy manufacturing capabilities

Xcell Biosciences Inc., an instrumentation company focused on cell and gene therapy applications, has expanded its collaboration with AmplifyBio, a rapidly growing contract development and manufacturing organization, through the installation of a new AVATAR Foundry system as part of Xcellbio’s beta access program.

October 04, 2024

Vol.50 No.37

In Brief

McKesson to acquire controlling stake in Florida Cancer Specialists & Research Institute’s Core Ventures

McKesson Corp. has signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures LLC (Core Ventures).

September 06, 2024

Vol.50 No.33

McKesson oncologist survey report details the state of cell and gene therapy adoption and barriers

YOU MAY BE INTERESTED IN

Genetic “Trojan horse” selectively kills cancer cells linked to Kaposi’s sarcoma, UC Davis study shows

An overlooked immune cell population may offer new direction for cell and gene therapy

John Zaia, virologist and gene therapy pioneer, dies at 82

OmniaBio opens commercial manufacturing facility in Canada, bringing cell and gene therapies to patients

Xcell Biosciences, AmplifyBio expand collaboration with cell and gene therapy manufacturing capabilities

McKesson to acquire controlling stake in Florida Cancer Specialists & Research Institute’s Core Ventures

Renew today!

Subscriber content

Never miss an issue!

Login